TrialJNCI cancer spectrum2024

Derazantinib alone and with atezolizumab in metastatic urothelial carcinoma with activating FGFR aberrations.

Andrea Necchi et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.